Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors
Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors
复制标题
DOI：
10.1097/jto.0b013e3181e9db73
复制
发表时间：
2010-09-01
影响因子：
20.4
通讯作者：
Mok, Tony
中科院分区：
文献类型：
--
作者：
Lin, Chia-Chi;Hsu, Hsin-Hsin;Mok, Tony
先前对随机临床研究中肿瘤样本中表皮生长因子受体（EGFR）突变状态的探索性分析表明，EGFR激活突变的患者比野生型EGFR患者有更好的生存。我们分析了晚期非小细胞肺癌患者既往参与治疗临床试验的肿瘤样本的EGFR序列，比较了EGFR突变阳性或阴性患者的化疗反应和生存期。来自122例患者的肿瘤样本可用于分析，其中58例（47.5%）患者存在EGFR突变。在105例IIIB/IV期患者中，EGFR突变患者的化疗反应率高于野生型EGFR患者（44.6%对30.6%,p = 0.162）。不吸烟和腺癌患者的寿命比吸烟的男性（p = 0.0139）和吸烟的男性（p = 0045）长。突变型和野生型EGFR患者的生存期无差异（p = 0 2159），野生型和突变型EGFR患者的一线化疗无进展生存期无差异（6.6个月vs 6.1个月）。在东亚晚期非小细胞肺癌患者中，EGFR突变患者的化疗反应率高于野生型EGFR患者，这一趋势无统计学意义
Introduction: Previous exploratory analysis of epidermal growth factor receptor (EGFR) mutational status in tumor samples from randomized clinical studies suggested that patients with activating mutation of the EGFR had better survival than those harboring wild-type EGFRMethods: We analyzed the EGFR sequence of tumor samples from advanced state non-small cell lung cancer patients previously participated in treatment clinical trials Responses to chemotherapy and survival of EGFR mutation-positive or -negative patients were comparedResults: Tumor samples from 122 patients were available for analysis EGFR mutation was present in 58 patients (47 5%) In 105 stage IIIB/IV patients, there was a nonstatistically significant trend toward a higher chemotherapy response rate of patients with mutated EGFR than those with wild-type EGFR (44 6% versus 30 6%, p = 0 162) Female. never-smoking, and adenocarcinoma patients lived longer than male (p = 0 0139), smoking (p = 0045). or nonadenocarcinoma (p = 0 0151) patients There was no difference in the survival of patients with mutated or wild-type EGFR (p = 0 2159) There was no difference in progression-free survival of first-line chemotherapy between patients with wild-type or mutation in EGFR (6 6 months versus 6 1 months)Conclusion: There is a nonstatistically significant trend toward a higher chemotherapy response rate in patients with mutated EGFR than those with wild-type EGFR EGFR gene mutation is not a predictive biomarker for progression-free and overall survival to cytotoxic chemotherapy in East Asians with advanced non-small cell lung cancer